A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : PV / polycythemia vera

[Related PubMed/MEDLINE]
Total Number of Papers: 1460
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   PV  (>> Co-occurring Abbreviation)
Long Form:   polycythemia vera
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2016 A t(11;14)(p13;q11.2) in myelofibrosis following polycythemia vera. MF
2016 Acquired uniparental disomy of chromosome 9p in hematologic malignancies. aUPD, MPNs
2016 Acute Lymphoblastic Leukemia in the Course of Polycythemia Vera: A Case Report and Review of Literature. ALL
2016 Acute Lymphoblastic Leukemia Transformation in Polycythemia Vera: A Rare Phenomenon. ALL, HU
2016 After 10years of JAK2V617F: Disease biology and current management strategies in polycythaemia vera. ---
2016 Analysis of thrombosis and bleeding complications in patients with polycythemia vera: a Turkish retrospective study. ---
2016 Anesthetic management of a patient with polycythemia vera for neurosurgery. ---
2016 Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera. ET, MPN, NGS, PMF
2016 Application of mutant JAK2V617F for in vitro generation of red blood cells. EPO, HSCs, mJAK2, RBCs, wJAK2
10  2016 Association of TNF polymorphisms with JAK2 (V617F) myeloproliferative neoplasms in Brazilian patients. ET, MPNs, PMF, TNF-alpha
11  2016 Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry. ET, MPN, PMF
12  2016 Blood donation and risk of polycythemia vera. CIs, ORs, SIRs
13  2016 Bone mineral density and microarchitecture in patients with essential thrombocythemia and polycythemia vera. DXA, ET, HR-pQCT
14  2016 Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy. MPN-SAF, PGIC, PSIS, QOL
15  2016 Characteristics and treatment of polycythemia vera patients in clinical practice: a multicenter chart review on 1476 individuals in Germany. ---
16  2016 Characterization and Prognosis Significance of JAK2 (V617F), MPL, and CALR Mutations in Philadelphia-Negative Myeloproliferative Neoplasms ET, Ph-negative MPNs, PMF
17  2016 Characterization of CD34+ hematopoietic progenitor cells in JAK2V617F and CALR-mutated myeloproliferative neoplasms. ET, HPCs, HSCs, MF, MPN
18  2016 Chronic lymphocytic leukemia and myeloproliferative neoplasms concurrently diagnosed: clinical and biological characteristics. CLL, ET, MPN, PMF
19  2016 Clinical Characteristics of Cerebrovascular Pathology with Patients Suffering from Ph-Negative Myeloproliferative Disease. CVD, ET, MPD, PM
20  2016 Clinical Features of 294 Turkish Patients with Chronic Myeloproliferative Neoplasms. ET, MPNs
21  2016 Clinical features of Japanese polycythemia vera and essential thrombocythemia patients harboring CALR, JAK2V617F, JAK2Ex12del, and MPLW515L/K mutations. ET, NAP
22  2016 Coexisting JAK2V617F and CALR Exon 9 Mutation in Essential Thrombocythemia. CALR, ET, PMF
23  2016 Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype? ET, PMF
24  2016 Comprehensive Gene expression meta-analysis and integrated bioinformatic approaches reveal shared signatures between thrombosis and myeloproliferative disorders. DEGs, ES, ET, MPDs
25  2016 Construction of polycythemia vera protein interaction network and prediction of related biological functions. OMIM
26  2016 Correlation between JAK2 allele burden and pulmonary arterial hypertension and hematological parameters in Philadelphia negative JAK2 positive myeloproliferative neoplasms. An Egyptian experience. ET, PAH, PMF
27  2016 Detection of CALR Mutation in Clonal and Nonclonal Hematologic Diseases Using Fragment Analysis and Next-Generation Sequencing. CML, ET, MPNs, PMF
28  2016 Detection of JAK2 Exon 12 Mutations in JAK2 V617F-Negative Polycythemia Vera Patients by Cloning Technique. ARMS
29  2016 Diffuse large B-cell lymphoma and polycythemia vera discovered at the onset - a rare association and its possible importance in lymphoma prognosis. DLBCL, MPNs, NHL, R-CHOP
30  2016 Do we need antiplatelet therapy in thrombocytosis? Contra. Proposal for an individualized risk-adapted treatment. ET, MPN, RT
31  2016 Extensive Bone Marrow Necrosis and Osteolytic Lesions in a Case of Acute Myeloid Leukemia Transformed from Polycythemia Vera. AML, BMN
32  2016 Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera. CI, HC, HR
33  2016 From leeches to personalized medicine: evolving concepts in the management of polycythemia vera. MPN
34  2016 Genetic and Pharmacologic Targeting of Alox5 Attenuates JAK2V617F Induced Polycythemia Vera in Mice. ALOX5
35  2016 Genetic Characteristics of Polycythemia Vera and Essential Thrombocythemia in Korean Patients. ET, MPN, SNPs
36  2016 Health care setting and severity, symptom burden, and complications in patients with Philadelphia-negative myeloproliferative neoplasms (MPN): a comparison between university hospitals, community hospitals, and office-based physicians. CH, ET, MPN, OB-P, UH
37  2016 High frequency of JAK2 exon 12 mutations in Korean patients with polycythaemia vera: novel mutations and clinical significance. ---
38  2016 Homozygous calreticulin mutations in patients with myelofibrosis lead to acquired myeloperoxidase deficiency. CALR, EPX, ET, GP, JAK2, MF, MPNs, MPO, mRNA
39  2016 Hormonal and Reproductive Factors and Risk of Myeloproliferative Neoplasms in Postmenopausal Women. CI, ET, HT, MPN
40  2016 How We Identify and Manage Patients with Inadequately Controlled Polycythemia Vera. JAK/STAT, MPN, PPV-MF, sAML
41  2016 Idiopathic erythrocytosis: a study of a large cohort with a long follow-up. FE, IE
42  2016 Impact of JAK2V617F Mutation Burden on Disease Phenotype in Chinese Patients with JAK2V617F-positive Polycythemia Vera (PV) and Essential thrombocythemia (ET). ET, RT-PCR
43  2016 Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001-12. CEL, CML, ET, IRRs, IRs, MDS, MPNs, NHWs, RS
44  2016 Incidence, Survival and Prevalence Statistics of Classical Myeloproliferative Neoplasm in Korea. ET, HIRA, KNCIDB, MF, MPN
45  2016 Insights into the Structural Features Essential for JAK2 Inhibition and Selectivity. HCV, JAK2, MPNs, SAR
46  2016 Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms. ET, HDACi, MPN
47  2016 JAK-2 V617F mutation increases heparanase procoagulant activity. CML, ET, PMF, TF, TFPI
48  2016 JAK2 exon 12 mutant mice display isolated erythrocytosis and changes in iron metabolism favoring increased erythropoiesis. ---
49  2016 JAK2 V617F stimulates proliferation of erythropoietin-dependent erythroid progenitors and delays their differentiation by activating Stat1 and other nonerythroid signaling pathways. EPO
50  2016 JAK2V617F Allele Burden Measurement in Peripheral Blood of Iranian Patients with Myeloproliferative Neoplasms and Effect of Hydroxyurea on JAK2V617F Allele Burden. ET, HU, MPNs, PMF, qRT-PCR
51  2016 Management of polycythaemia vera: a critical review of current data. ---
52  2016 Masked polycythaemia vera: presenting features, response to treatment and clinical outcomes. BCSH
53  2016 Minihepcidin peptides as disease modifiers in mice affected by beta-thalassemia and polycythemia vera. ---
54  2016 Molecular biomarkers of thrombosis in myeloproliferative neoplasms. CALR, ET, IPSET-thrombosis, MPN, PMF
55  2016 Molecular testing for JAK2, MPL, and CALR in myeloproliferative neoplasms. ET, PMF
56  2016 Myelofibrosis: an update on drug therapy in 2016. ET, MF, OS, PMF
57  2016 Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey. ET, MF, MPN, MPNs, QOL
58  2016 Myeloproliferative neoplasms: A decade of discoveries and treatment advances. CALR, CML, ET, MPL, MPN, PMF, WHO
59  2016 Myeloproliferative neoplasms: Current molecular biology and genetics. ASXL1, CALR, CBL, DNMT3A, ET, EZH2, HMGA2, IKZF1, MPNs, Ph-MPNs, PMF, SOCS, TET2, TP53
60  2016 Myeloproliferative neoplasms: Morphology and clinical practice. BM, ET, MPNs, prePMF
61  2016 Myocardial infarction as a thrombotic complication of essential thrombocythemia and polycythemia vera. ET, MI
62  2016 New Strategies in Myeloproliferative Neoplasms: The Evolving Genetic and Therapeutic Landscape. ET, MF, MPN
63  2016 Optimal therapy for polycythemia vera and essential thrombocythemia: Preferred use of interferon therapy based on phase 2 trials. ET
64  2016 Outcome Disparities in Caucasian andNon-Caucasian Patients With Myeloproliferative Neoplasms. ET, MPNs
65  2016 Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib. MF
66  2016 Pegylated interferon for the treatment of early myelofibrosis: correlation of serial laboratory studies with response to therapy. CALR, ET, JAK2, MF, MPNs, Peg-IFN, PET, PPV
67  2016 PO-19 - Platelet (PLT) adhesion under flow condition in essential thrombocythemia (ET) and polycythemia vera (PV) is variably influenced according to patient mutational status. AIRC, CalR, ET, PLT
68  2016 PO-26 - Whole blood rotational thromboelastometry (ROTEM) to detect hypercoagulability in patients with myeloproliferative neoplasms (MPN). AIRC, ET, MPN, ROTEM
69  2016 PO-59 - Hemorheologic disturbances as thrombosis risk factor in patients with some myeloproliferative neoplasms. ALL, BNP, CRT, VTE, WBV
70  2016 Polycythemia and Thrombocytosis. ET, MPNs
71  2016 Polycythemia is associated with bone loss and reduced osteoblast activity in mice. EPO, rEPO, WT
72  2016 Practice Patterns in the Diagnosis and Treatment of Polycythemia Vera in the Post-JAK2 V617F Discovery Era. MPN
73  2016 Quantification of IGF-1 Receptor May Be Useful in Diagnosing Polycythemia Vera-Suggestion to Be Added to Be One of the Minor Criterion. EEC, IGF-1R
74  2016 Rapidly progressed aortic stenosis in a patient with previous diagnosis of polycythemia vera and post-polycythemia vera myelofibrosis. AS
75  2016 Recent advances in understanding myelofibrosis and essential thrombocythemia. ET, MK, MPNs, PMF
76  2016 Recurrent Stroke with Rapid Development of Intracranial Stenoses in Polycythemia Vera. ---
77  2016 Risk factors for non-melanoma skin cancer in patients with essential thrombocythemia and polycythemia vera. ET, NMSC, OR
78  2016 Risk of second primary malignancies and survival of adult patients with polycythemia vera: A United States population-based retrospective study. AER, SEER, SIR, SPM
79  2016 Ruxolitinib in the treatment of polycythemia vera: patient selection and special considerations. ---
80  2016 Second line therapies in polycythemia vera: What is the optimal strategy after hydroxyurea failure? HU
81  2016 Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease. HU, MPN, SAF, TSS
82  2016 TERT rs2736100 A>C SNP and JAK2 46/1 haplotype significantly contribute to the occurrence of JAK2 V617F and CALR mutated myeloproliferative neoplasms - a multicentric study on 529 patients. ET, MPN, PMF, SNP, TERT
83  2016 The 2016 revision of WHO classification of myeloproliferative neoplasms: Clinical and molecular advances. BM, ET, PMF, prePMF
84  2016 The Calreticulin gene and myeloproliferative neoplasms. CALR, ET, MPL, PMF
85  2016 The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF). TSS-C
86  2016 The expression of Death Inducer-Obliterator (DIDO) variants in Myeloproliferative Neoplasms. CML, DIDO, ET, MPN, PMF
87  2016 The Polymorphisms in LNK Gene Correlated to the Clinical Type of Myeloproliferative Neoplasms. CML, ET, MPN, PMF
88  2016 The potential role of hematocrit control on symptom burden among polycythemia vera patients: Insights from the CYTO-PV and MPN-SAF patient cohorts. ---
89  2016 Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera? AML, HU
90  2016 [Diagnosis and treatment of polycythaemia vera: state of the art]. ---
91  2016 [Diagnosis of latent polycythemia vera: A clinician's opinion]. ---
92  2016 [Not Available]. CALR, CML, ET, MPN, PMF
93  2016 [Not Available]. JAK, MF
94  2016 [Research Progress on CALR Mutation in the Myeloproliterative Neoplasm -Review]. CMPN
95  2016 [The assessment of symptomatic burden among Ph/BCR- ABL negative myeloproliferative neoplasm patients]. ET, MPN, MPN-SAF-TSS, PMF
96  2015 A rapid, highly accurate method for quantifying CALR mutant allele burden in persons with myeloproliferative neoplasms. CALR, CML, ET, HES, MPNs, PMF
97  2015 Acute Non-Atherosclerotic ST-Segment Elevation Myocardial Infarction in an Adolescent with Concurrent Hemoglobin H-Constant Spring Disease and Polycythemia Vera. STEMI
98  2015 Anagrelide hydrochloride and ruxolitinib for treatment of polycythemia vera. HU
99  2015 Analysis of JAK2V617F mutation in Jordanian patients with myeloproliferative neoplasms. ET, IMF, MPNs
100  2015 Aspirin-responsive, migraine-like transient cerebral and ocular ischemic attacks and erythromelalgia in JAK2-positive essential thrombocythemia and polycythemia vera. ET, MIAs